Review Article — ACS Pharmacology & Translational Science, 2026
The Future of Epigenetics
Emerging Technologies and Clinical Applications
13 FDA-Approved Drugs
2,200+ Clinical Trials
$6.77B Market by 2033
120,000+ Publications
Review Article — ACS Pharmacology & Translational Science, 2026
Emerging Technologies and Clinical Applications
Epigenetics is the study of heritable changes in gene expression that occur without alterations to the DNA sequence itself. Instead of changing the genetic code, epigenetic mechanisms act as a layer of control on top of DNA — turning genes on or off through chemical modifications to DNA, histone proteins, and RNA molecules.
This comprehensive review analyzes data from over 120,000 epigenetic-related publications (2000–2024) in the CAS Content Collection to map the explosive growth of this field. The four main epigenetic mechanisms — DNA methylation, histone modifications, noncoding RNAs (ncRNAs), and chromatin remodeling — are each discussed in depth, along with their roles in health and disease.
The clinical impact has been transformative: 13 FDA-approved epigenetic drugs are now on the market, primarily targeting blood cancers, with 37+ ongoing clinical trials expanding into metabolic, neurological, and inflammatory disorders. The global epigenetics market, valued at $1.84 billion in 2023, is projected to reach $6.77 billion by 2033.
The CAS Content Collection contains over 120,000 epigenetics-related publications spanning 2000–2024, revealing a dramatic acceleration in research output. Publication counts have grown from a few hundred per year in the early 2000s to over 12,000 annually. Patents and funding have followed a similar trajectory, underscoring the commercial significance of the field.
Epigenetic regulation works through four main classes of chemical modifications that control gene expression without changing DNA sequence. Each mechanism operates at a different level — from modifying DNA itself to reshaping the protein scaffolding around which DNA is wound.
The most studied epigenetic mark. Methyl groups (–CH3) are added to cytosine bases at CpG sites, typically silencing gene expression. Catalyzed by DNMT enzymes: DNMT1 maintains patterns during cell division, while DNMT3a/3b establishes new ones. Critical for X-chromosome inactivation, genomic imprinting, and embryonic development. Aberrant methylation — such as silencing of tumor suppressors — is a hallmark of cancer.
CpG sites are locations in DNA where a cytosine (C) is followed by a guanine (G). The “p” refers to the phosphodiester bond connecting them. These sites are like switches — when methyl groups are added to them, nearby genes get turned off. Think of it like putting a cap on a pen: the pen (gene) still exists, but it can’t write (express).
DNMTs (DNA methyltransferases) are the enzymes that add these methyl caps. DNMT1 is the “maintenance crew” that copies existing methylation patterns when cells divide, while DNMT3a and DNMT3b are the “installation team” that creates new methylation marks during embryonic development.
Post-translational modifications (acetylation, methylation, phosphorylation, ubiquitination) to histone proteins alter how tightly DNA is wound. Acetylation loosens chromatin (activating genes), while deacetylation tightens it (silencing genes). Regulated by HATs (writers) and HDACs (erasers). Aberrant histone marks disrupt gene expression and contribute to cancer, neurodegeneration, and other diseases.
HATs and HDACs: Think of DNA as thread wound around spools (histones). HATs (histone acetyltransferases) loosen the thread by adding acetyl groups, making genes accessible for reading. HDACs (histone deacetylases) do the opposite — they tighten the winding, hiding genes from the cell’s reading machinery. Many cancer drugs work by blocking HDACs to re-activate tumor suppressor genes.
Regulatory RNA molecules that do not encode proteins but control gene expression. miRNAs (most studied, peaked 2021) degrade target mRNAs. lncRNAs (rapidly growing) guide chromatin-modifying complexes to specific genomic locations. piRNAs silence transposable elements in germline cells. Together, ncRNAs add a sophisticated post-transcriptional layer of gene regulation.
ATP-dependent protein complexes (SWI/SNF, ISWI, CHD, INO80) physically restructure nucleosomes — sliding, ejecting, or reorganizing them to expose or conceal gene regulatory regions. SWI/SNF mutations are found in approximately 20% of human cancers. The least-studied of the four mechanisms but increasingly recognized as critical for development and disease.
Beyond the four classical mechanisms, six emerging research areas are transforming our understanding of epigenetic regulation and opening new therapeutic possibilities.
The study of over 170 distinct chemical modifications to RNA. The most abundant, N6-methyladenosine (m6A), is regulated by “writers” (METTL3/14), “erasers” (FTO, ALKBH5), and “readers” (YTHDF proteins). These modifications impact mRNA stability, splicing, and translation, with links to cancer, obesity, and neurological disorders.
Epitranscriptomics applies the same logic as DNA epigenetics, but to RNA molecules. Just as DNA can be modified by methylation, RNA can also receive chemical modifications that change its behavior.
The field uses a memorable framework:
The most-studied RNA modification, m6A (N6-methyladenosine), affects how long an mRNA molecule survives, how it gets processed, and how efficiently it makes protein. Disruptions in this system have been linked to cancer, obesity, and neurological disorders.
Uses deactivated Cas9 (dCas9) fused with epigenetic effector domains to modify epigenetic marks at specific genomic locations without altering the DNA sequence. CRISPRi represses genes; CRISPRa activates them. Offers a potentially reversible alternative to permanent gene editing, with rapidly growing research output (tripling from 2020 to 2024).
Traditional CRISPR gene editing permanently cuts DNA to disable genes. Epigenetic CRISPR is different — it uses a deactivated version of Cas9 (called dCas9) that can find specific genes but can’t cut them. Instead, it carries epigenetic tools that either silence (CRISPRi = CRISPR interference) or activate (CRISPRa = CRISPR activation) genes by modifying the chromatin around them. Because no DNA is cut, the changes are potentially reversible — a major advantage for therapeutic applications where permanent genome changes carry risks.
Single-cell technologies (scATAC-seq, scBS-seq) reveal epigenetic heterogeneity between individual cells within tissues. Spatial epigenomics, the newest frontier, maps epigenetic marks in their tissue context. Together, they enable understanding of tumor heterogeneity, developmental trajectories, and cell-type-specific regulation.
The most active emerging area (300–400 papers/year). Environmental factors — diet, stress, toxins, lifestyle choices — can induce heritable epigenetic changes that persist across generations without DNA sequence alterations. This has profound implications for public health policy: parental exposures to pollution or nutritional stress may affect children and grandchildren through transgenerational epigenetic inheritance.
Transgenerational epigenetic inheritance challenges a long-held biological assumption: that acquired characteristics cannot be passed to offspring. While DNA sequence is not changed, epigenetic modifications induced by environmental exposures can be transmitted through egg and sperm cells to future generations.
A well-known example: the Dutch Hunger Winter (1944–45) showed that children of mothers who experienced famine during pregnancy had higher rates of obesity and cardiovascular disease decades later — and some effects were visible in grandchildren who were never directly exposed. This has major implications for environmental policy: industrial pollution and dietary patterns today may affect the health of future generations through epigenetic mechanisms.
Epigenetic dysregulation underlies a wide spectrum of human diseases. Across all disease-related epigenetics publications, cancer dominates at 47%, followed by aging (9%), infection, neurological disorders, metabolic diseases, and autoimmune conditions. The field is actively expanding beyond oncology.
The largest area of epigenetic disease research (47%). Aberrant DNA methylation, histone modifications, and ncRNA dysregulation drive tumor development. TP53 is the most-studied gene (1,200+ papers), followed by CDKN2A, H19, c-myc, and IGF2. Tumor suppressor silencing through promoter hypermethylation and oncogene activation through hypomethylation are key mechanisms. Breast and colorectal cancers are the most intensively studied tumor types.
Epigenetic clocks are computational models that predict biological age from DNA methylation patterns. Key milestones: Horvath’s clock (2013, 353 CpG sites, multi-tissue), Hannum’s clock (blood-based), GrimAge (mortality prediction), and DunedinPACE (pace of aging). These tools enable research into longevity, age-related disease, and the effects of interventions like caloric restriction or exercise on biological aging.
Your chronological age (years since birth) and your biological age (how old your body actually “acts”) can differ significantly. Epigenetic clocks measure biological age by analyzing DNA methylation patterns at specific genomic locations.
For example, Horvath’s clock examines methylation at 353 specific CpG sites and uses a mathematical model to predict biological age. A 50-year-old with the methylation pattern of a 60-year-old has accelerated biological aging — potentially indicating higher disease risk. Conversely, some lifestyle interventions (exercise, caloric restriction) appear to slow the epigenetic clock.
GrimAge goes further by predicting mortality risk, while DunedinPACE measures the pace of aging (how fast you’re aging right now), making it useful for evaluating anti-aging interventions in clinical trials.
Aberrant epigenetic modifications contribute to Alzheimer’s, Parkinson’s, and Huntington’s diseases. Altered DNA methylation and histone acetylation patterns affect genes critical for neuronal function. HDAC inhibitors show promise in preclinical models for restoring memory and synaptic plasticity in neurodegenerative conditions.
Type 2 diabetes is linked to DNA methylation changes in insulin signaling genes (e.g., INS, IGF1R). Obesity alters the epigenome via FTO gene methylation. Autoimmune diseases — rheumatoid arthritis, lupus, multiple sclerosis — involve epigenetic dysregulation of immune cell differentiation and function, with global DNA hypomethylation as a common feature.
Epigenetic drugs (epi-drugs) work by reversing aberrant epigenetic modifications to restore normal gene expression. The therapeutic landscape is dominated by HDAC inhibitors (59% of publications), followed by DNMT inhibitors (13%). A total of 13 drugs have received FDA approval, primarily for hematological malignancies, with an active clinical pipeline diversifying into non-cancer indications.
Traditional cancer drugs target genetic mutations or rapidly dividing cells. Epi-drugs take a fundamentally different approach: they reverse the chemical modifications that are causing genes to behave abnormally. For example, an HDAC inhibitor doesn’t kill cancer cells directly — it re-opens chromatin so that silenced tumor suppressor genes can function again, essentially reminding cancer cells how to behave normally. This is why epi-drugs are sometimes called “reprogramming” therapies.
The epigenetic drug clinical trial landscape has expanded dramatically, with nearly 2,200 trials registered on ClinicalTrials.gov over 25 years. Phase II trials dominate (57%), reflecting the exploratory nature of many combination therapy strategies. Notably, 62% of trials involve already-approved drugs, suggesting extensive label expansion efforts.
| Phase | % |
|---|---|
| Early Phase I | 1% |
| Phase I | 32% |
| Phase II | 57% |
| Phase III | 9% |
| Phase IV | 1% |
| Status | % |
|---|---|
| Not yet recruiting | 4% |
| Recruiting | 17% |
| Active | 7% |
| Completed | 36% |
| Withdrawn | 36% |
Using dCas9 fused with epigenetic effectors to modify marks at specific loci. Offers targeted, potentially reversible therapy without permanent DNA changes. Early-stage clinical development for conditions including sickle cell disease.
Proteolysis-targeting chimeras that recruit the ubiquitin-proteasome system to selectively degrade epigenetic regulators like BRD4 and EZH2. Emerging as an alternative to traditional enzyme inhibition.
PROTACs (Proteolysis Targeting Chimeras) are a next-generation approach. Instead of just blocking an enzyme, PROTACs act as molecular matchmakers: one end grabs the target protein (e.g., BRD4), while the other end recruits the cell’s natural protein-disposal system (ubiquitin-proteasome). The target protein gets tagged for destruction and eliminated entirely. This “degrade rather than inhibit” strategy can overcome drug resistance that develops with traditional inhibitors.
Short synthetic nucleic acids targeting epigenetic regulatory RNAs (e.g., lncRNAs like HOTAIR and MALAT1) for degradation. Enable precise silencing of oncogenic noncoding transcripts.
Synthetic molecules designed to restore the function of tumor-suppressive miRNAs that are silenced in cancer. Aim to re-establish normal post-transcriptional gene regulation in tumor cells.
Pelabresib (CPI-0610) — A BET inhibitor in Phase III trials for myelofibrosis (MANIFEST-2 study). Received FDA Fast Track Designation in 2019. Ziftomenib (KO-539) — A menin-KMT2A inhibitor that received FDA Breakthrough Therapy designation in 2024 for relapsed/refractory NPM1-mutant AML.
Apabetalone (RVX-208) — A selective BET inhibitor targeting BD2 domains, in Phase I/II for end-stage kidney disease. Previously received Breakthrough Therapy Designation for major adverse cardiovascular events. Larsucosterol (DUR-928) — First-in-class epigenetic regulator in Phase II for alcoholic hepatitis. Received Breakthrough Therapy Designation in 2024.
Vafidemstat (ORY-2001) — A selective LSD1 inhibitor in Phase II for borderline personality disorder, representing a novel neuropsychiatric application of epigenetic therapy. Givinostat — An HDAC inhibitor approved in the EU for Duchenne muscular dystrophy, demonstrating epigenetic drug expansion beyond oncology.
Epigenetic biomarkers are molecular signatures derived from epigenetic modifications that can be used for disease diagnosis, prognosis, and treatment monitoring. Unlike genetic mutations, epigenetic changes are often reversible and tissue-specific, making them particularly valuable for non-invasive liquid biopsy approaches.
The most clinically advanced class. SEPT9 methylation enables non-invasive colorectal cancer screening through blood tests (Epi proColon). MGMT methylation predicts response to Temozolomide in glioblastoma, guiding treatment decisions. BRCA1 and p16 promoter hypermethylation serve as cancer hallmarks.
The SEPT9 methylation test (marketed as Epi proColon) represents a practical breakthrough: instead of requiring a colonoscopy to screen for colorectal cancer, a simple blood test can detect abnormal DNA methylation patterns shed by tumor cells into the bloodstream. Similarly, MGMT methylation testing in glioblastoma patients helps doctors decide whether to prescribe Temozolomide — patients with methylated MGMT promoters respond significantly better to this chemotherapy drug. These examples illustrate how epigenetic biomarkers are enabling precision medicine: matching specific treatments to patients based on their molecular profiles.
Specific histone marks serve as disease indicators. H3K27me3 levels correlate with cancer prognosis. H3K4me1 marks active enhancers and can identify cell-type-specific regulatory states. Global histone acetylation levels have prognostic value in multiple cancer types.
Circulating miRNAs offer non-invasive diagnostic potential. miR-21 and miR-155 are dysregulated across multiple cancer types. lncRNAs like HOTAIR and MALAT1 show diagnostic and prognostic value. Extracellular vesicle-packaged ncRNAs are emerging as stable blood-based biomarkers.
ATAC-seq chromatin accessibility profiles enable tumor classification and subtyping. Chromatin accessibility signatures can distinguish cancer subtypes and predict treatment response. Still emerging, but rapid technical advances are enabling clinical translation.
A rich ecosystem of experimental technologies supports epigenetic research, spanning four major categories: DNA methylation analysis (bisulfite sequencing, methylation arrays), histone modification detection (ChIP-seq, CUT&RUN), noncoding RNA analysis (RNA-seq, CLIP-seq), and chromatin remodeling profiling (ATAC-seq, DNase-seq). Next-generation approaches like CUT&Tag, spatial ATAC-seq, and long-read nanopore sequencing are expanding the frontiers.
The integration of epigenomic profiling with clinical data is enabling precision medicine approaches. Pharmacoepigenomics guides drug selection — for example, MGMT methylation status determines whether glioblastoma patients will benefit from Temozolomide. Liquid biopsies using circulating epigenetic markers offer non-invasive monitoring. AI and machine learning are accelerating biomarker discovery and epigenetic pattern recognition.
Pharmacoepigenomics is the epigenetic equivalent of pharmacogenomics. While pharmacogenomics uses genetic variations to guide drug choice, pharmacoepigenomics uses epigenetic profiles. Because epigenetic marks are dynamic and influenced by environment and lifestyle, they can provide more actionable and timely information for treatment decisions than static genetic variants alone.
Privacy of epigenetic data that can reveal lifestyle and environmental exposures. Informed consent challenges for epigenetic testing that may reveal information about family members. Risk of discrimination based on epigenetic profiles. Ethical concerns about germline epigenetic editing and its intergenerational consequences.
Need for regulatory guidelines governing epigenetic therapies, especially germline modifications. Intellectual property considerations for epigenetic modifications and diagnostic tests. Data protection laws must evolve to address the unique sensitivity of epigenetic information, which reflects both genetic predisposition and environmental history.
Environmental justice: pollution exposure disproportionately affects disadvantaged communities, with transgenerational epigenetic consequences. Responsibility for preventing harmful environmental exposures takes on new significance. Public education is needed to distinguish epigenetics from genetics and avoid deterministic misinterpretations.
AI-driven epigenomic analysis for pattern recognition. Long-read sequencing (nanopore, PacBio) for direct detection of DNA and RNA modifications. Multi-omics integration combining epigenomics, transcriptomics, and proteomics. Enhanced single-cell and spatial resolution technologies.
Expanding therapeutic applications beyond cancer to metabolic, neurological, and inflammatory disorders. Combination therapies pairing epi-drugs with immunotherapy and targeted agents. Development of tissue-specific and isoform-selective inhibitors to reduce off-target effects.
Functional validation of epigenetic marks — distinguishing causal from correlative changes. Understanding the crosstalk between epigenetic mechanisms. Elucidating how epigenetic states are established, maintained, and erased during development and in disease.
lncRNAs extensively modified by m6A, influencing stability and function. RNA modification patterns as new diagnostic biomarkers. Small-molecule inhibitors targeting the epitranscriptomic machinery. Understanding DNA–RNA modification crosstalk for comprehensive therapeutic strategies.
Despite rapid progress, significant challenges remain: (1) Technological limitations in achieving single-cell spatial resolution. (2) Ethical concerns about germline epigenetic editing. (3) Complexity of epigenetic–genetic–environmental interactions. (4) Reproducibility across cell types and tissues. (5) Drug resistance and off-target effects. (6) Need for standardized biomarker validation protocols.
The landscape of epigenetic research has undergone a remarkable transformation, evolving from a specialized area of molecular biology into a mainstream biomedical discipline with profound implications for human health.
This review cites over 600 references spanning epigenetics, molecular biology, clinical trials, and drug development. For the complete reference list, please refer to the original publication on PMC.
B2B Content
Any content, beautifully transformed for your organization
PDFs, videos, web pages — we turn any source material into production-quality content. Rich HTML · Custom slides · Animated video.